Aclasta (zoledronic acid): Uses, Dosage & Side Effects

What it's for (Indications)

Zoledronic acid, marketed under various brand names such as Zoldic, is a highly potent bisphosphonate primarily utilized for a range of bone-related conditions affecting both malignant and non-malignant etiologies.
Its indications include the treatment and prevention of osteoporosis in postmenopausal women and men, as well as the treatment of glucocorticoid-induced osteoporosis.
Furthermore, it is a cornerstone therapy for managing Paget's disease of bone, a chronic disorder characterized by abnormal bone remodeling.
In oncology settings, zoledronic acid is critically important for treating hypercalcemia of malignancy (HCM), a severe complication of advanced cancer, and for preventing skeletal-related events (SREs), such as pathological fractures, spinal cord compression, and the need for radiation or surgery to bone, in patients with multiple myeloma and bone metastases from solid tumors like breast or prostate cancer.
These uses underscore its broad therapeutic utility in skeletal health.

Dosage Information

Type	Guideline
Standard	The dosage regimen for zoledronic acid (e.g., Zoldic) varies significantly based on the specific indication, patient's renal function, and desired therapeutic outcome. For the treatment and prevention of osteoporosis, including glucocorticoid-induced osteoporosis, the recommended dose is typically 5 mg administered intravenously as a single infusion once yearly. For Paget's disease of bone, a single 5 mg intravenous infusion is usually sufficient. In the context of hypercalcemia of malignancy, a 4 mg intravenous infusion is generally given as a single dose, which may be repeated if necessary after a minimum of 7 days, provided calcium levels remain elevated. For the prevention of skeletal-related events in patients with bone metastases from solid tumors or multiple myeloma, the standard dose is 4 mg administered intravenously every 3 to 4 weeks. All intravenous infusions must be administered slowly over at least 15 minutes, and adequate hydration is crucial before and after administration, particularly for oncology indications, to mitigate the risk of renal toxicity. Careful monitoring of serum creatinine, calcium, phosphate, and magnesium levels is essential throughout treatment, and dose adjustments or deferral of treatment may be required for patients with impaired renal function, especially those with creatinine clearance below 35 mL/min.

Type

Guideline

Standard

The dosage regimen for zoledronic acid (e.g., Zoldic) varies significantly based on the specific indication, patient's renal function, and desired therapeutic outcome. For the treatment and prevention of osteoporosis, including glucocorticoid-induced osteoporosis, the recommended dose is typically 5 mg administered intravenously as a single infusion once yearly. For Paget's disease of bone, a single 5 mg intravenous infusion is usually sufficient. In the context of hypercalcemia of malignancy, a 4 mg intravenous infusion is generally given as a single dose, which may be repeated if necessary after a minimum of 7 days, provided calcium levels remain elevated. For the prevention of skeletal-related events in patients with bone metastases from solid tumors or multiple myeloma, the standard dose is 4 mg administered intravenously every 3 to 4 weeks. All intravenous infusions must be administered slowly over at least 15 minutes, and adequate hydration is crucial before and after administration, particularly for oncology indications, to mitigate the risk of renal toxicity. Careful monitoring of serum creatinine, calcium, phosphate, and magnesium levels is essential throughout treatment, and dose adjustments or deferral of treatment may be required for patients with impaired renal function, especially those with creatinine clearance below 35 mL/min.

Safety & Warnings

Common Side Effects

Patients receiving zoledronic acid (e.
g.
, Zoldic) may experience a range of side effects, which can vary in severity and incidence.
Common adverse reactions, often referred to as 'acute phase reactions,' frequently occur within the first three days following administration, especially after the first dose.
These symptoms can resemble influenza, presenting as fever, fatigue, myalgia (muscle pain), arthralgia (joint pain), and headache.
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or constipation are also commonly reported.
More serious, albeit less frequent, side effects warrant careful consideration.
These include osteonecrosis of the jaw (ONJ), a condition characterized by bone breakdown in the jaw, often associated with dental procedures, cancer, or concomitant medications.
Atypical femoral fractures (AFFs), which are unusual subtrochanteric or diaphyseal femur fractures, have been reported, typically occurring with prolonged use.
Renal impairment, ranging from transient elevation in serum creatinine to acute renal failure, can occur, particularly with rapid infusion, dehydration, or pre-existing renal dysfunction.
Hypocalcemia, sometimes severe, may also develop, especially in patients with pre-existing parathyroid abnormalities or vitamin D deficiency.
Other potential serious adverse events include ocular inflammation (e.
g.
, uveitis, scleritis) and, rarely, atrial fibrillation.
Patients should be advised to report any new or worsening symptoms promptly.

Serious Warnings

Black Box Warning: Zoledronic acid (e.g., Zoldic) does not carry a formal FDA Black Box Warning. However, clinicians and patients must be fully aware of several serious safety concerns that require vigilant monitoring and proactive management. **Renal Toxicity:** Acute renal failure has been reported, particularly in patients with pre-existing renal impairment, dehydration, or when the infusion rate is too rapid. Dosage adjustments are required for patients with mild-to-moderate renal impairment, and the drug is contraindicated in severe renal impairment. Adequate hydration before and after infusion is crucial. **Osteonecrosis of the Jaw (ONJ):** Cases of ONJ, often associated with dental procedures, have been reported, primarily in cancer patients. A dental examination and preventive dentistry should be considered prior to treatment, especially in patients with risk factors such as cancer, concomitant chemotherapy, corticosteroids, poor oral hygiene, or pre-existing dental disease. Invasive dental procedures should be avoided during treatment if possible. **Atypical Femoral Fractures (AFFs):** Low-trauma subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, typically after long-term use. Any new thigh, hip, or groin pain should prompt immediate evaluation to rule out a fracture. **Hypocalcemia:** Severe and symptomatic hypocalcemia can occur, particularly in patients with pre-existing hypoparathyroidism, vitamin D deficiency, or severe renal impairment. Pre-existing hypocalcemia must be corrected before initiating therapy, and adequate calcium and vitamin D supplementation is essential throughout treatment. Patients should be informed of these significant risks and report any concerning symptoms immediately.
Zoledronic acid (e.
g.
, Zoldic) carries several critical warnings that necessitate careful patient selection, monitoring, and management.
One primary concern is renal toxicity, which can manifest as an increase in serum creatinine and, in severe cases, acute renal failure.
This risk is heightened with rapid infusion, dehydration, concomitant nephrotoxic drugs, and pre-existing renal impairment; therefore, careful assessment of renal function (creatinine clearance) is mandatory before each dose, and the infusion time must be strictly adhered to.
Hypocalcemia can occur or worsen, particularly if pre-existing hypocalcemia is not corrected before treatment or if vitamin D deficiency is present; thus, serum calcium levels must be normalized, and patients should receive adequate calcium and vitamin D supplementation.
Osteonecrosis of the jaw (ONJ) is a significant risk, especially in cancer patients, those undergoing invasive dental procedures, or individuals with poor oral hygiene.
A dental examination with preventive dentistry should be considered prior to initiation, especially in patients with risk factors.
Atypical femoral fractures (AFFs) have been reported, primarily with long-term bisphosphonate use; patients experiencing new thigh, hip, or groin pain should be evaluated for a femoral fracture.
Severe and occasionally incapacitating bone, joint, and/or muscle pain has also been reported.
Pregnancy and lactation represent contraindications or require careful risk-benefit assessment due to potential fetal harm and unknown excretion into breast milk.

How it Works (Mechanism of Action)

Zoledronic acid (e.g., Zoldic) is a highly potent, nitrogen-containing bisphosphonate that exerts its therapeutic effects by specifically targeting and inhibiting osteoclast-mediated bone resorption. Upon intravenous administration, zoledronic acid demonstrates a high affinity for bone mineral, rapidly localizing to sites of active bone remodeling, particularly within the bone matrix. Once internalized by osteoclasts, which are the bone-resorbing cells, it interferes with the mevalonate pathway, specifically by inhibiting the enzyme farnesyl pyrophosphate synthase. This inhibition leads to a disruption in the post-translational prenylation of key regulatory proteins essential for osteoclast function, morphology, and survival. Consequently, osteoclast activity is significantly reduced, leading to a decrease in the rate of bone turnover and a net increase in bone mineral density. In conditions like osteoporosis, this mechanism helps to strengthen bone structure and reduce fracture risk. In malignancy-related bone diseases, it reduces the release of calcium from bone, thereby controlling hypercalcemia, and decreases the destructive activity of tumor-induced osteoclasts, which can slow the progression of bone metastases and reduce skeletal-related events. Its potent antiresorptive action is central to its efficacy across its diverse indications.